#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Candida infection Cervix carcinoma Pulmonary alveolar haemorrhage Polycystic liver disease PIK3CA-activated mutation Ovarian cancer stage IV Tourette's disorder Cytomegalovirus infection Extranodal marginal zone B-cell lymphoma (MALT type) Non-renal cell carcinoma of kidney Neuroendocrine carcinoma of the skin Renal cell carcinoma Myxofibrosarcoma Thermal burn Rhabdoid tumour More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia refractory – Treatment Lymphangiosarcoma – Basic Information Antisynthetase syndrome – Trials in Disease Haemophilia B without inhibitors – Trials in Disease Osteosarcoma – Treatment Encephalitis autoimmune – Trials in Disease Mucous membrane pemphigoid – Diagnostics Waldenstrom’s macroglobulinaemia recurrent Sarcoma – Diagnostics Hepatoblastoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    F44/10 VG801-2 AZD1163 Magnesium Citrate Obicetrapib Tenofovir Disoproxil Brinzolamide Ruzasvir Azelastine ZIRCONIUM (89ZR) GIRENTUXIMAB Quizartinib Dihydrochloride Wt1 Mrna Dc Terlipressin GSK5460025A Rebisufligene Etisparvovec Nvdx3 Fasudil Hydrochloride Regn7257 GSK5764227 Metreleptin More therapies…

    Learn about Your Condition

    Corneal graft failure Tendon injury Vestibular disorder Osteosarcoma metastatic Cholangiocarcinoma Atrial fibrillation Device related infection Developmental hip dysplasia Generalised anxiety disorder Perineal injury Ventricular tachycardia Bronchopulmonary aspergillosis CADASIL Endometrial cancer recurrent Diabetes insipidus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hairy cell leukaemia
    Investigated Drugs:
    • Cladribine
    • Vemurafenib
    • Rituximab
    Italy

  • Study on Psilocybin-Assisted Therapy for Patients with Severe Alcohol Use Disorder

    Recruiting

    2 1
    Investigated Diseases:
    • Alcohol abuse
    Investigated Drugs:
    • Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
    Belgium

  • Study on the Safety of Repeated Intra-Arterial Infusion of Mesenchymal Stem Cells for Children and Adolescents with Refractory Epilepsy

    Recruiting

    1 1 1
    Investigated Diseases:
    • Rasmussen encephalitis
    Investigated Drugs:
    • Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
    Spain

  • Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Dabrafenib
    • Vorasidenib
    • Ivosidenib
    Norway

  • Study on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase and Alprostadil for Patients with Peyronie’s Disease

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Peyronie’s disease
    Investigated Drugs:
    • ALPROSTADIL
    • Vibrio Alginolyticus Collagenase
    Italy

  • Study on the Effects of Rikkunshito on Functional Dyspepsia in Primary Care Patients

    Recruiting

    3 1
    Investigated Diseases:
    • Dyspepsia
    Investigated Drugs:
    • RIKKUNSHITO
    Belgium
Previous Page
1 … 290 291 292 293 294 … 1,650
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!